Lutris Pharma will present updated Phase 2 trial results for LUT014 Gel at the upcoming EADV Congress, showcasing its potential in treating oncology-related skin issues.

Lutris Pharma presents encouraging results from a Phase 2 study of LUT014 Gel, demonstrating its effectiveness against acneiform rash from anti-EGFR therapies, enhancing patients' treatment adherence.

Lutris Pharma is set to present data from its Phase 2 trial of LUT014 gel, aimed at treating acneiform rash induced by EGFR inhibitors, at ESMO 2025.

Lutris Pharma has appointed Dr. Sumant Ramachandra as its new CEO, promising to enhance cancer treatments and patient quality of life.

At the AACR Annual Meeting 2025, Lutris Pharma unveiled promising data for its LUT014 gel, demonstrating efficacy in treating acneiform rash in cancer patients, enhancing care outcomes.

Lutris Pharma is set to present findings from a Phase 2 study of LUT014, a topical treatment aimed at combating skin side effects common with anti-cancer therapies, at AACR 2025.

Lutris Pharma announces a $30 million funding round aimed at enhancing the development of an innovative treatment for skin toxicity in cancer therapy, promising better patient outcomes.